following a full submission:
talquetamab (Talvey®) is accepted for use within NHSScotland.
Indication under review: as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.
In an uncontrolled phase I/II study, patients with relapsed and refractory multiple myeloma who had at least 3 prior therapies (including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody), and received talquetamab 0.8 mg/kg every two weeks, achieved an objective response rate of 70%.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
Medicine details
- Medicine name:
- talquetamab (Talvey)
- SMC ID:
- SMC2863
- Indication:
As monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.
- Pharmaceutical company
- Janssen-Cilag Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 08 June 2026